Compare · DXCM vs PODD
DXCM vs PODD
Side-by-side comparison of DexCom Inc. (DXCM) and Insulet Corporation (PODD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PODD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 3.4x PODD ($9.92B).
- PODD has been more active in the news (12 items in the past 4 weeks vs 9 for DXCM).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Insulet Corporation
- Price
- $89.16-2.09%
- $143.03-1.68%
- Market cap
- $33.65B
- $9.92B
- 1M return
- -
- -13.31%
- 1Y return
- -
- -56.92%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2007
- News (4w)
- 9
- 12
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest PODD
- President and CEO Mcevoy Ashley bought $162,217 worth of shares (1,100 units at $147.47), increasing direct ownership by 5% to 23,731 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Insulet Corporation
- Insulet downgraded by Truist with a new price target
- Insulet downgraded by Wells Fargo with a new price target
- Insulet downgraded by Analyst with a new price target
- Insulet downgraded by BTIG Research
- Insulet downgraded by Leerink Partners with a new price target
- SEC Form 10-Q filed by Insulet Corporation
- Insulet downgraded by Oppenheimer
- Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits